Results of the primary objective (prostate-specific antigen [PSA] <0.2 ng/mL at week 25 [to convert to micrograms per liter, multiply by 1.0]) have been previously reported.15 In this prespecified secondary analysis, we report the results from HRQOL analysis using the Functional Assessment of Cancer Therapy–Prostate (FACT-P) questionnaire. This evidence concerns the gene KLK3 and cancer.